KYTX (Kyverna Therapeutics) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kyverna Therapeutics's Free Cash Flow for the three months ended in Jun. 2024 was $-25.20 Mil. Kyverna Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Kyverna Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Kyverna Therapeutics's current FCF Yield % is -33.81%.

The historical rank and industry rank for Kyverna Therapeutics's FCF Margin % or its related term are showing as below:

During the past 3 years, the highest FCF Margin % of Kyverna Therapeutics was -414.50%. The lowest was -525.00%. And the median was -469.75%.

KYTX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.87
* Ranked among companies with meaningful FCF Margin % only.

Kyverna Therapeutics FCF Margin % Historical Data

The historical data trend for Kyverna Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics FCF Margin % Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-414.50

-525.00

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
FCF Margin %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Kyverna Therapeutics's FCF Margin %

For the Biotechnology subindustry, Kyverna Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyverna Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's FCF Margin % falls into.

Kyverna Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kyverna Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-53.031	/	0
	=	%

Kyverna Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-25.203	/	0
	=	%

Kyverna Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024